CSK Kinase Enzyme System

产品编号：V2982 品牌：promega 原厂货号：V2982
产品分类：蛋白质检测与分析 > 酶检测和活性分析 > 激酶检测
应用分类：

包装：

1mg

运保温度:

-70℃

到货周期：

登录后查看

标准价：

￥客户可见

会员价：

￥客户可见

积分：

客户可见分

登录之后可加入购物车购买，请您

运费与支付说明：

1.含干冰类产品有运费；

2. 必须现金付款或有信用额度的会员才可以直接发货，否则需要等待现金付款信息。

描述：

说明		在 Sf9 昆虫细胞中，我们通过杆状病毒表达 N 端带 GST 标签的重组全长人源 CSK 。 CSK 是细胞质内的一个酪氨酸激酶，可通过磷酸化 c-src C 端的酪氨酸残基来下调 c-src 的酪氨酸激酶活性。研究人员已用酵母双杂交系统鉴定 CSK 相关蛋白。 CSK 的 Src 同源体 3 （ SH3 ）结构域与 PEP 的一个脯氨酸富集区相关联， PEP 是在造血细胞中表达的一个蛋白酪氨酸磷酸酶。这种关联是高度特异的，推测 PEP 可能是 T 细胞和其他造血细胞中 CSK 的效应因子和（或）调节因子。 ADP-Glo^™ Kinase Assay （ADP-Glo^™ 激酶检测试剂盒）是一种发光法激酶检测试剂盒，用于检测激酶反应产生的 ADP 含量： ADP 转化为 ATP 后， ATP 即可作为 Ultra-Glo^™ 萤光素酶催化反应的底物，产生光信号。发光信号与 ADP 的量和激酶活性正相关。该试剂盒适合检测化合物对纯化的多种激酶活性的影响，使之成为初筛和激酶选择性概况分析的理想工具。 ADP-Glo^™ 激酶检测试剂盒可用于检测几乎所有可生成 ADP 的酶类 ( 如激酶或 ATP 酶 ) 的活性， ATP 浓度可高达 1 mM 。激酶酶系统的组成： • 激酶： CSK ， 10μg ( 人源，重组全长蛋白 ) ； MW : ~78kDa 。 • 底物： Poly (4:1 Glu, Tyr) Peptide 。其它组分：反应缓冲液， DTT ， MnCl₂ 。 CSK NCBI 数据库入口。人类激酶酶系统及其应用。
特点		• 在实验室内即可筛选更多的化合物： ADP-Glo^™ 激酶检测试剂盒与激酶酶系统的优化组合，使您可以迅速方便地开始实验。 • 完整的系统：激酶酶系统包含重组激酶、激酶的最适底物、反应缓冲液、以及使用前需加入缓冲液的 DTT 和 MnCl₂ 。 • 可得到可靠结果： ADP-Glo^™ 激酶检测试剂盒提供了宽广的动态范围、方便的操作方法、以及更好的灵敏度，产生的数据更可靠。
操作手册		CSK Application Notes. Kinase-Lot-Specific Data Sheets. ADP-Glo™ Kinase Assay Technical Manual #TM313.
储存条件		收到试剂盒后，请将激酶轻微离心后分装成小份，储存于 –70°C ；其他组分储存于 –20°C 。
参考文献		1. Partanen, J. et al. (1991) Oncogene 6 , 2013–8. 2.Cloutier, J.F. et al. (1996) EMBO J. 15 , 4909–18.
专利/免责声明		For Cat.# V9251: Patents Pending. U.S. Pat. No. 7,770,310, Australian Pat. No. 2003268489 and other patents pending. U.S. Pat. Nos. 6,602,677 and 7,241,584, Australian Pat. Nos. 754312 and 785294 and other patents and patents pending. The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673. Licensed from Lonza Nottingham Ltd. under U.S. Pat. Nos. 6,599,711 and 6,911,319 and other pending and issued patents.

原厂资料：

Recombinant full-length human CSK was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. CSK is a cytoplasmic tyrosine kinase that has been shown to downregulate the tyrosine kinase activity of c-src through tyrosine phosphorylation of the c-src carboxy terminus. A yeast 2-hybrid system has been used to identify proteins associated with CSK. The Src homology-3 (SH3) domain of CSK associates with a proline-rich region of PEP, a protein-tyrosine phosphatase expressed in hemopoietic cells. This association is highly specific, and it is speculated that PEP may be an effector and/or regulator of CSK in T cells and other hemopoietic cells.

ADP-Glo™ Kinase Assay is a luminescent kinase assay that measures ADP formed from a kinase reaction; ADP is converted into ATP, which is a substrate in a reaction catalyzed by Ultra-Glo™ Luciferase that produces light. The luminescent signal positively correlates with ADP amount and kinase activity. The assay is well suited for measuring the effects chemical compounds have on the activity of a broad range of purified kinases, making it ideal for both primary screening as well as kinase selectivity profiling. The ADP-Glo™ Kinase Assay can be used to monitor the activity of virtually any ADP-generating enzyme (e.g., kinase or ATPase) using up to 1mM ATP.

Kinase Enzyme System contains:

Kinase: CSK, 10μg (Human, recombinant full-length). MW: ~78kDa.
Substrate: Poly (4:1 Glu, Tyr) Peptide.
Other: Reaction Buffer, DTT, MnCl2.

CSK NCBI Database Entry.

Human Kinase Enzyme Systems and Applications.

Features - Benefits

Profile More Compounds In-House: ADP-Glo™ Kinase Assay + Kinase Enzyme System is optimized so that you are up and running in no time.
Complete Systems: The Kinase Enzyme Systems include a recombinant kinase enzyme, a substrate appropriate for the enzyme, a reaction buffer, DTT and supplemental reagents as needed.
Obtain Reliable Results: The broad dynamic range, the ease of use and better sensitivity obtained with ADP-Glo™ Kinase Assay result in less ambiguous data.

Notes

Kinase Enzyme System manufactured by SignalChem.
Bulk quantities available upon request.

References

1.Partanen, J. et al. (1991) Oncogene 6, 2013–8.
2.Cloutier, J.F. et al. (1996) EMBO J. 15, 4909–18.